Medicine
Diltiazem 30 mg tablet
Diltiazem 30 mg tablet is a generic prescription medicine for oral use, made by 12 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 25°C (77°F), excursions permitted to 15° to 30°C (59° to 86°F).
Key facts
- Active ingredient (INN)
- Diltiazem
- Brand
- Sold under the generic name
- Strength
- 30 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 100 tablets, 500 tablets, 120 tablets and 20 more
- Manufacturers
- Alembic PharmaceuticalsIndiaViona PharmaceuticalsIndiaZydus LifesciencesIndiaScieGen PharmaceuticalsBryant Ranch PrepackOceanside PharmaceuticalsTeva PharmaceuticalsAmerican Health PackagingChartwell RXCoupler
- Origin register
- US FDA, United States
- Storage
- Store at 25°C (77°F), excursions permitted to 15° to 30°C (59° to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- C05AE03 Diltiazem
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 5 November 1992
- Identifiers
- RxCUI 831054, 831102, 831103 +1DailyMed set ID 74bab197-f719-48c0-ac84-c0cf0087b45a, 51abce7b-e3d1-44b5-bccc-d463150d0bba, 2cd92b83-075e-b069-e063-6294a90a9fff +11NDC 46708-781, 62135-333, 67046-1492 +11Application ANDA217633, ANDA074093, ANDA216521 +3
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 tablet, film coated in 1 bottle | 46708-781-31 | Alembic PharmaceuticalsIndia | 14 November 2025 |
| 500 tablet, film coated in 1 bottle | 46708-781-71 | Alembic PharmaceuticalsIndia | 14 November 2025 |
| 100 tablet, film coated in 1 bottle | 62332-781-31 | Alembic PharmaceuticalsIndia | 14 November 2025 |
| 500 tablet, film coated in 1 bottle | 62332-781-71 | Alembic PharmaceuticalsIndia | 14 November 2025 |
| 100 tablet in 1 bottle | 72578-199-01 | Viona PharmaceuticalsIndia | 25 May 2026 |
| 500 tablet in 1 bottle | 72578-199-05 | Viona PharmaceuticalsIndia | 25 May 2026 |
| 100 tablet in 1 bottle | 70771-1929-1 | Zydus LifesciencesIndia | 25 May 2026 |
| 500 tablet in 1 bottle | 70771-1929-5 | Zydus LifesciencesIndia | 25 May 2026 |
| 120 tablet in 1 bottle | 62135-333-12 | Chartwell RX | 17 June 2024 |
| 100 tablet in 1 bottle | 68682-006-10 | Oceanside Pharmaceuticals | 25 December 2010 |
| 500 tablet in 1 bottle | 68682-006-50 | Oceanside Pharmaceuticals | 25 December 2010 |
| 100 tablet in 1 bottle | 50228-481-01 | ScieGen Pharmaceuticals | 26 September 2022 |
| 500 tablet in 1 bottle | 50228-481-05 | ScieGen Pharmaceuticals | 26 September 2022 |
| 1000 tablet in 1 bottle | 50228-481-10 | ScieGen Pharmaceuticals | 26 September 2022 |
| 30 tablet in 1 bottle | 50228-481-30 | ScieGen Pharmaceuticals | 26 September 2022 |
| 100 tablet, film coated in 1 bottle | 0093-0318-01 | Teva Pharmaceuticals | 22 December 1995 |
| 500 tablet, film coated in 1 bottle | 0093-0318-05 | Teva Pharmaceuticals | 28 December 1995 |
| 90 tablet, film coated in 1 bottle | 63629-3659-1 | Bryant Ranch Prepack | 27 March 2024 |
| 90 tablet in 1 bottle | 71335-2373-1 | Bryant Ranch Prepack | 23 May 2024 |
| 100 blister pack in 1 carton / 1 tablet, film coated in 1 blister pack | 60687-717-01 | American Health Packaging | 27 March 2023 |
| 30 tablet in 1 blister pack | 67046-1492-3 | Coupler | 29 January 2025 |
| 10 tablet in 1 bottle, plastic | 82868-036-10 | Northwind Health | 18 January 2024 |
| 30 tablet, film coated in 1 blister pack | 0615-8032-39 | Vangard Labs | 10 May 2016 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 5 November 1982 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Diltiazem 30 mg tablet.
Other strengths and forms of Diltiazem
Clinical summary
Diltiazem is a calcium channel blocker indicated for the management of chronic stable angina and angina due to coronary artery spasm. It is available as extended-release capsules, tablets and extended-release tablets for oral and intravenous use. MedsAcross supplies Diltiazem for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about DiltiazemFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Cardizem prescribing information (Bausch Health) · U.S. National Library of Medicine, DailyMed
Need Diltiazem 30 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.